company background image
COCP

Cocrystal Pharma NasdaqCM:COCP Stock Report

Last Price

US$3.15

Market Cap

US$25.7m

7D

16.2%

1Y

-52.8%

Updated

04 Feb, 2023

Data

Company Financials +

Cocrystal Pharma, Inc.

NasdaqCM:COCP Stock Report

Mkt Cap: US$25.7m

COCP Stock Overview

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases.

COCP fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Cocrystal Pharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cocrystal Pharma
Historical stock prices
Current Share PriceUS$3.15
52 Week HighUS$7.56
52 Week LowUS$1.74
Beta0.92
1 Month Change55.94%
3 Month Change31.80%
1 Year Change-52.80%
3 Year Change-51.82%
5 Year Change-94.29%
Change since IPO-98.71%

Recent News & Updates

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Oct 11

Recent updates

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Oct 11

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Aug 15

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Aug 14
Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Aug 08

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Mar 19
We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Nov 19
Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Aug 06
We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Jun 14

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

May 05
We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

Cocrystal Pharma updates on COVID-19 antiviral development programs

May 03

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Mar 13
Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Jan 24
What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Cocrystal sees 2021 cash burn of $800k a month

Jan 11

Cocrystal Pharma to test CDI-45205 against coronaviruses

Dec 22

Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

Dec 20
Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

Shareholder Returns

COCPUS PharmaceuticalsUS Market
7D16.2%-0.5%1.7%
1Y-52.8%4.6%-9.6%

Return vs Industry: COCP underperformed the US Pharmaceuticals industry which returned 4.3% over the past year.

Return vs Market: COCP underperformed the US Market which returned -8.5% over the past year.

Price Volatility

Is COCP's price volatile compared to industry and market?
COCP volatility
COCP Average Weekly Movement12.5%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: COCP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: COCP's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a13Sam Leehttps://www.cocrystalpharma.com

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection.

Cocrystal Pharma, Inc. Fundamentals Summary

How do Cocrystal Pharma's earnings and revenue compare to its market cap?
COCP fundamental statistics
Market CapUS$25.65m
Earnings (TTM)-US$38.02m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
COCP income statement (TTM)
RevenueUS$0
Cost of RevenueUS$11.84m
Gross Profit-US$11.84m
Other ExpensesUS$26.18m
Earnings-US$38.02m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-4.67
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did COCP perform over the long term?

See historical performance and comparison